SCM
KURA icon

Superstring Capital Management’s Kura Oncology KURA Stock Holding History

Superstring Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-157,959
Closed -$1.38M – 43
2024
Q4 		$1.38M Buy
+157,959
New +$2.27M 1.19% 23
2024
Q3 		– Sell
-36,242
Closed -$746K – 39
2024
Q2 		$746K Buy
+36,242
New +$745K 0.94% 28

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Superstring Capital Management's KURA Position: Q1 2025 in Review

Superstring Capital Management sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 157,959 shares — an estimated $1.38M sold.

Superstring Capital Management first reported a position in KURA in Q2 2024 and held it in 2 quarters. The position peaked at $1.38M in Q4 2024. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

  • Superstring Capital Management reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
  • Superstring Capital Management sold 157,959 Kura Oncology shares in Q1 2025, an estimated $1.38M.
  • Superstring Capital Management first reported a position in Kura Oncology in Q2 2024 and held it in 2 quarters.
  • Superstring Capital Management's Kura Oncology position peaked at $1.38M in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.